Sustainability | January 23, 2025
Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Subscribe To Our Newsletter & Stay Updated
